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Abstract  31 
Hepatitis B virus (HBV) vaccination is recommended for all susceptible chronic pre-32 
hemodialysis and hemodialysis patients. This study assessed the immunogenicity 33 
of HBV vaccines (adjuvanted and non-adjuvanted) in chronic kidney disease 34 
patients vaccinated at the Hospital Clinic of Barcelona (Spain) between January 35 
2007 and July 2012. In addition, the costs for the health system were evaluated 36 
according to the proportion of vaccine responders after receiving either vaccine. 37 
Patients receiving three doses of hepatitis B adjuvanted vaccine were three times 38 
more likely to seroconvert than patients immunized with non-adjuvanted vaccines, 39 
OR 3.56 (95% CI 1.84-6.85). This resulted in fewer patients requiring a second 40 
course of HBV vaccination and fewer outpatient visits, saving more than €9,500 41 
per 100 patients. The higher immunogenicity of the adjuvanted HBV vaccine would 42 
counterbalance the lower costs associated with the non-adjuvanted vaccine.  43 
  44 
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Introduction 45 
Chronic kidney disease patients are at high risk for hepatitis B virus (HBV) infection 46 
due to increased exposure to blood products, shared hemodialysis equipment, 47 
frequent skin breaches, and immunodeficiency.1,2 Despite preventive measures to 48 
protect these patients against HBV infection, outbreaks continue to be reported in 49 
dialysis units.3,4 50 
 51 
HBV vaccination is recommended for all susceptible chronic pre-hemodialysis and 52 
hemodialysis patients, with regular monitoring of antibody levels to ensure they 53 
remain above 10 IU/ml.5 Conventional HBV vaccines are poorly immunogenic in 54 
patients with renal insufficiency,1 with low response rates and suboptimal antibody 55 
titers, and require frequent boosters to maintain protection.6 The efficacy of 56 
conventional vaccines in chronic kidney disease patients has been reported as 57 
55.4% one month after the third dose.7 To improve the immunological response to 58 
HBV vaccination, patients should be vaccinated as soon as possible in the course 59 
of the renal disease.8 60 
 61 
A Hepatitis B vaccine adjuvanted with AS04 (Fendrix®, GlaxoSmithKline) has been 62 
licensed for use in this population in Europe since 2005. In a comparative clinical 63 
study in 165 pre-hemodialysis and hemodialysis patients, protective levels of 64 
specific humoral antibodies (antibodies against the hepatitis B surface antigen 65 
(anti-HBs) titers ≥ 10 IU/ml) were observed in 74.4% of Fendrix recipients (N = 82) 66 
one month after the third dose, compared with 52.4% of patients in the control 67 
group who received a double dose of a commercially available HBV vaccine (N = 68 
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83).9 The adjuvanted vaccine has a good safety profile, with clinically-acceptable 69 
reactions similar to those of non-adjuvanted HBV vaccines.10 70 
 71 
In the region of Catalonia, Spain, the adjuvanted vaccine was acquired for the last 72 
time in 2010, and only non-adjuvanted HBV vaccines (Engerix-B® 20 µg, 73 
GlaxoSmithKline and HBVAXPRO® 40µg, Sanofi-Pasteur) have been acquired in 74 
succeeding years (coinciding with the economic crisis) for chronic kidney disease 75 
patients.  76 
 77 
The objectives of this study were to assess the immunogenicity of HBV vaccination 78 
with the adjuvanted and non-adjuvanted vaccines in chronic kidney disease 79 
patients and to evaluate the economic costs for the health system according to the 80 
immunogenicity achieved after receiving either vaccine.  81 
 82 
Results 83 
Characteristics of the study population 84 
A total of 267 patients with chronic kidney disease were included in the analysis, a 85 
mean of 49 per year. The mean age of participants included was 68.1 years (SD 86 
12.76) and 62.9% were male. Twenty patients presented immunocompromised 87 
conditions, 13 had a cancer diagnosis, of which six were kidney-related cancers. 88 
No patient presented HIV infection. Thirty-three patients were already in 89 
hemodialysis at the beginning of the vaccination schedule, and two patients who 90 
were not in hemodialysis started it before the administration of the third dose of 91 
5 
 
vaccine. Other demographic and clinical characteristics of subjects by type of HBV 92 
received are shown in Table 1. 93 
 94 
Factors associated with response to the hepatitis B vaccine 95 
Our results show that 51.7% of patients presented an immunological response 96 
after three doses. Proportion of immunogenicity shows differences between 97 
adjuvanted and non-adjuvanted vaccines (see Table 1).  Patients receiving three 98 
doses of hepatitis B adjuvanted vaccine were three times more likely to 99 
seroconvert than patients immunized with non-adjuvanted vaccines, OR 3.56 (95% 100 
CI 1.84-6.85) (see Table 2). Only 43.3% of patients aged ≥ 65 years presented 101 
levels of anti-HBs ≥10 IU/mL, and had a worse response than those aged <65, 102 
ORa 0.35 (95% CI 0.21-0.60). There were no significant differences in the immune 103 
response between immunocompromised and non-immunocompromised or 104 
between patients on hemodialysis or not.  105 
 106 
Cost analysis  107 
The lowest probability weighted cost per patient was the one associated with 108 
Fendrix® (€ 795.59), assessing the use of Fendrix® as the most convenient 109 
(Figure 1). According to sensitivity analysis, EngerixX-B® or HBVAXPRO® would 110 
be more convenient than Fendrix®, should Fendrix® price per dose increase from 111 
the current value of 28.3 euros to about 48.11 or to 53 euros, respectively (Figure 112 
2).    113 
 114 
Discussion 115 
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To our knowledge, this is one of the few studies to evaluate the economic costs 116 
associated with the type of HBV vaccine administered to chronic kidney disease 117 
patients. It is nested within the context of a change in the type of HBV vaccine 118 
acquired by the regional department of health, coinciding with the economic crisis 119 
in Spain. The results suggest that the decision to use non-adjuvanted, less 120 
immunogenic (and in this case, cheaper) HBV vaccines might also result in higher 121 
costs for the health system and for patients.  122 
 123 
The differing seroconversion rates found in patients vaccinated with the adjuvant 124 
ASO4 vaccine and the non-adjuvanted HBV vaccines are consistent with 125 
previously reported studies.11–13 The benefits in the immune response resulting 126 
from the use of the adjuvanted vaccine could also be augmented by including the  127 
longer persistence of anti-HBs antibody titers,14 although this was not assessed in 128 
our study. As previously reported, older patients presented lower seroconversion 129 
rates, which were, however, higher with the adjuvanted vaccine.15,16 Unlike other 130 
studies, we found no differences in the vaccine response according to the 131 
creatinine level or the hemodialysis status. This might be explained by the limited 132 
sample size of our study. 133 
 134 
From an economic perspective, the differences translate into fewer patients 135 
requiring a second course of HBV vaccination and fewer outpatient visits, with a 136 
saving of more than €9,500 per 100 patients. Even with an increase of 70% in the 137 
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adjuvanted vaccine price, the costs associated with this strategy were lower than 138 
those associated with non-adjuvanted vaccines. 139 
 140 
Our study has some limitations. A higher sample size would have allowed us to 141 
obtain more robust conclusions and, perhaps, to determine other factors 142 
associated with the vaccine response. Secondly, there was no available 143 
information on previously-administered doses of vaccine with the hepatitis B 144 
component, although the age of the patients included suggests it is very unlikely 145 
that they had been vaccinated according to the Spanish routine immunization 146 
schedule. Thirdly, there was no patient follow-up, and therefore, the duration of 147 
antibody levels could not be assessed: this would potentially have added to the 148 
benefits of the adjuvanted vaccine. Fourthly, the cost per dose of vaccine and of 149 
outpatient visits in our hospital may differ between health care centers and vaccine 150 
prices may vary between countries and other time periods.  151 
 152 
In conclusion, considering that patients not responding to the first three doses of 153 
the first HBV vaccine course will required at least three more doses, with the 154 
consequent outpatient visits, the accumulated costs of the non-adjuvanted and 155 
adjuvanted vaccines differ widely. The higher immunogenicity achieved with the 156 
adjuvanted HBV vaccine outweighs the lower costs associated with the non-157 
adjuvanted vaccine.  158 
 159 
Materials and Methods 160 
Study characteristics 161 
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We performed a retrospective study to assess the immunogenicity of adjuvanted 162 
and non-adjuvanted HBV vaccines in chronic kidney disease patients vaccinated at 163 
the Hospital Clinic of Barcelona (Spain) between January 2007 and July 2012. 164 
 165 
Laboratory methods 166 
Serological screening for HBsAg was made in all chronic kidney disease patients. 167 
The response to HBV vaccination was detected by measuring anti-HBs and was 168 
determined by enzyme immunoassay system using AUSAB AxSYM particles 169 
(ABBOTT®). Seroprotection was defined as anti-HBs titers ≥10 IU/mL. Patients not 170 
reaching this threshold were considered non-responders.  171 
 172 
Hepatitis B immunization protocol 173 
In non-immune patients (HBsAg negative), four doses of HBV vaccine were 174 
recommended (0, 1, 2, 6 months regimen). The vaccines used during the study 175 
period were Engerix-B® (GlaxoSmithKline (2 x 20μg)), HBVAXPRO® (Sanofi-176 
Pasteur (40μg)) and Fendrix® (GlaxoSmithKline (20μg)), which includes the AS04 177 
adjuvant. Only patients who received three or more doses of HBV vaccine were 178 
included in the analysis. 179 
Approximately one month after the third dose, a blood sample was obtained. For 180 
responders, a fourth dose was recommended six months after the first. For non-181 
responders, the immunization schedule was reinitiated with three further doses 182 
followed by anti-HBs determination. If the patient again presented anti-HBs <10 183 
IU/mL, more doses were not recommended.  184 
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 185 
Data collection and analysis 186 
Variables were limited to information recorded in the medical records, including 187 
sex, creatinine level at initiation of the hepatitis B vaccination schedule, reported 188 
immunocompromised conditions (cancer, chemotherapy treatment, HIV), 189 
hemodialysis status, type of vaccine administrated (adjuvanted or non-adjuvanted), 190 
dates of administration of HBV vaccines, among others. The post-vaccination anti-191 
HBs level was the main endpoint. Vaccine safety-related variables were not 192 
collected, since a safety assessment was not an objective of this study.  193 
To evaluate factors independently associated with seroconversion after hepatitis B 194 
vaccination, we performed univariate and multivariable logistic regression 195 
analyses. The statistical analysis was made using the SPSS® v18.0 statistical 196 
package. Statistical significance was established as a p-value <0.05. 197 
 198 
For the cost analysis we compared costs per patient associated with the three 199 
vaccination strategies by developing a decision tree (Figure 1). Costs associated 200 
with each vaccination strategy were the price of each vaccine plus the cost of 201 
outpatient visits. (For vaccines we used official prices for 2011-2012 in Catalonia 202 
(Spain) of HBV vaccines. These were € 28.30 per dose for Fendrix®, € 26.09 per 203 
dose for  HBVAXPRO® and € 10.10 per dose for Engerix-B® (for which, two doses 204 
were administered at each visit and thus the total comparable cost was € 20.20 per 205 
visit).17 The cost of an outpatient medical visit at HCB was 137 €.18 The three 206 
strategies differed for the probability of needing a second vaccination course. Such 207 
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probability was given by the immunogenic response after the third doses of each 208 
hepatitis B vaccine.  209 
One way sensitivity analysis was performed on Fendrix price per dose.  210 
  211 
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Table 1.Immunogenic response after the third doses of hepatitis B vaccine was administered in patients with chronic kidney disease.  293 
 294 
 295 
      HBVAXPRO®  ENGERIX-B®  FENDRIX®  Vaccined population    
      Total Anti-HBs ≥ 10  Total Anti-HBs ≥ 10  Total Anti-HBs ≥ 10  Overall Anti-HBs ≥ 10    
      n (%)* n (%)**  n (%)* n (%)**  n (%)* n (%)**   n (%)* n (%)**  
p-
value¶ 
  Overall   152 (100) 70 (46.1)  56 (100) 25 (44.6)  59 (100) 43 (72.9)  267 (100) 138 (51.7)    
  95% CI       (38.1 - 54.0)      (31.6 - 57.7)      (61.5 - 84.2)      (45.7 - 57.7)    
Sex                                           
  Female   49 (32.2) 19 (38.8)  24 (42.9) 11 (45.8)  26 (44.1) 20 (76.9)  99 (37.1) 50 (50.5)  0.767 
  Male   103 (67.8) 51 (49.5)  32 (57.1) 14 (43.8)  33 (55.9) 23 (69.7)  168 (62.9) 88 (52.4)  
Age (years)                                    
  18 - 44   9 (5.9) 4 (44.4)  2 (3.6) 2 (100)  5 (8.5) 4 (80.0)  16 (6.0) 10 (62.5)  
0.001   45 - 64   47 (30.9) 31 (66.0)  20 (35.7) 11 (55.0)  13 (22.0) 12 (92.3)  80 (30.0) 54 (67.5)  
  ≥65   96 (63.2) 35 (36.5)  34 (60.7) 12 (35.3)  41 (69.5) 27 (65.9)  171 (64.0) 74 (43.3)  
Creatinine (mg/dL)                                    
  < 2   24 (15.8) 12 (50.0)  16 (28.6) 5 (31.3)  4 (6.8) 3 (75.0)  44 (16.5) 20 (45.5)  
0.620   2 - 4   77 (50.7) 36 (46.8)  29 (51.8) 15 (51.7)  37 (62.7) 26 (70.3)  143 (53.6) 77 (53.8)  
  > 4   51 (33.6) 22 (43.1)  11 (19.6) 5 (45.5)  18 (30.5) 14 (77.8)  80 (30.0) 41 (51.3)  
Immunocompromised                                
  Yes   9 (5.9) 4 (44.4)  9 (16.1) 4 (44.4)  2 (3.4) 1 (50.0)  20 (7.5) 8 (45.0)  0.836 
  No   143 (94.1) 66 (46.2)  47 (83.9) 21 (44.7)  57 (96.6) 43 (73.7)  247 (92.5) 129 (52.2)  
Hemodialysis                                    
  Yes   21 (14.5) 11 (52.4)  8 (14.8) 3 (37.5)  4 (6.8) 3 (75.0)  33 (12.8) 17 (51.5)  0.965 
  No   124 (85.5) 54 (43.5)  46 (85.2) 21 (45.7)  55 (93.2) 40 (72.7)  225 (87.2) 115 (51.1)  
                                    
* = columns percentage            
** = row percentage, values of non acceptable immunogenicity (Anti-HBs < 10 UI/mL) were omitted. 
95% CI= confidence interval 95% of the proportion of acceptable immunogenicity to each vaccine (Anti-HBs ≥ 10 UI/mL) 
¶ = chi-square test of distribution of total vaccinated population                          
 296 
 297 
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Table 2. Factors potentially associated with an immunogenic response after hepatitis B immunization in 298 
patients with chronic kidney disease.  299 
 300 
                  
      OR (95% CI)   p-value   ORa (95% CI) 
Sex                   
  Female   1 -           
  Male   1.12 (0.71 - 1.79)   0.767       
Age (years)                 
  < 65   1 -       1 - 
  ≥ 65   0.38 (0.23 - 0.64)   < 0.001   0.35 (0.21 - 0.60) 
Creatinine (mg/dL)                 
  < 2   1 -           
  2 - 4   1.38 (0.72 - 2.83)   0.364       
  > 4   1.32 (0.57 - 2.61)          
Immunocompromised          
  No   1 -          
  Yes   0.71 (0.33 - 1.87)   0.534      
Hemodialysis               
  No   1 -          
  Yes   1.02 (0.54 - 2.12)   0.965      
Hepatitis B Vaccine                 
  
non-
adjuvanted†   1 -       1 - 
  adjuvanted    3.24 (1.66 - 5.97)   <0.001   3.56 (1.84 - 6.85) 
                  
 301 
OR: odds ratio. 
ORa: odds ratio adjusted by multiple logistic regression model 
†= HBVAXPRO and Engerix-B were grouped together 
p-value= chi-square test 
 302 
 303 
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Figure 1. Decision tree and associated costs for each HBV vaccine.   304 
 305 
p1, p2 and p3 = immunogenicity of HBAXPRO, Engerix-B and Fendrix, respectively. 
 306 
 307 
 308 
 309 
 310 
Figure 2. One way sensitivity analysis on Fendrix® price per dose versus costs associated with other 311 
vaccines. 312 


